The short answer
Pathologic complete response means no invasive cancer was found in the tissue removed after neoadjuvant treatment. It is strongly encouraging, especially in triple-negative and HER2-positive breast cancer.
pCR means that when the breast tissue and sampled lymph nodes were examined under a microscope after neoadjuvant treatment, no residual invasive cancer was found.
The FDA recognizes two definitions: ypT0/is ypN0, which permits residual in situ disease, and the stricter ypT0 ypN0, which does not.
The 'y' means the staging was done after treatment and the 'p' means it was based on pathology rather than imaging.
The link between pCR and long-term outcome is strongest in triple-negative and HER2-positive breast cancer, and weaker in hormone receptor-positive, HER2-negative disease.
On this page
Choose how you want to read this
The whole article, with every detail and caution.
This page is for people who had treatment before surgery and see "pathologic complete response" (pCR) on their report. It focuses mostly on breast cancer, with a short note on other cancers.
What the term means
Did you have chemotherapy, targeted therapy or immunotherapy before surgery? That is called neoadjuvant treatment. After the operation, a pathologist looks at everything that was removed. That means the breast tissue and the lymph nodes that were sampled.
Pathologic complete response means no invasive cancer was found in any of it.
Not smaller. Not mostly gone. None that can be seen under the microscope in the tissue examined.
The exact wording matters a little
The FDA recognizes two definitions.
ypT0/is ypN0 — no invasive cancer left in the breast tissue that was removed, and none in the sampled nodes. Some residual ductal carcinoma in situ may still be there. This is the definition used most often.
ypT0 ypN0 — the stricter one. It requires that both invasive and in situ disease are gone.
Here is how to read the notation. The 'y' means the staging was done after treatment, not at diagnosis. The 'p' means it came from pathology, not from imaging. T stands for the tumor. N stands for the nodes.
Why is in situ disease usually allowed? The reason is practical. Outcome data track most closely with getting rid of invasive cancer. In situ disease has not broken through into nearby tissue, and it does not spread.
Why teams place weight on it
Neoadjuvant treatment gives your team something that adjuvant treatment (treatment given after surgery) cannot. It shows how your own cancer responded to your own drugs. Your team does not have to estimate benefit from population averages. They can see the result in the tissue.
Large pooled analyses of neoadjuvant trials have shown a clear pattern. People who achieve pCR have better event-free and overall survival than people with residual disease. But that link is not the same across all breast cancer. It is strongest in triple-negative and HER2-positive disease. Those subtypes respond best to chemotherapy, and pCR is most achievable there. The link is much weaker in hormone receptor-positive, HER2-negative cancer. In that group, much of the long-term benefit comes from years of endocrine (hormone-blocking) therapy rather than from chemotherapy before surgery.
So the same result carries different weight depending on your subtype. That is also why your oncologist may frame it differently from something you have read.
What pCR does not mean
It does not mean cure. Pathology can only report on the tissue that was removed. Cells elsewhere in the body are beyond its reach. A small number of people who achieve pCR do still have a recurrence.
That is why treatment usually goes on after surgery. Radiation may be advised, depending on the operation and the original stage. Endocrine therapy continues for hormone receptor-positive disease. HER2-directed treatment continues to finish the planned course. A pCR does not usually mean stopping everything.
If you did not achieve pCR
Most people do not. Residual disease is not a verdict on your treatment.
Real shrinkage without complete disappearance is a genuine response. And residual disease now guides care in its own right. It points to people who benefit from more treatment after surgery. In HER2-positive breast cancer with residual invasive disease, the KATHERINE trial showed a benefit from switching to trastuzumab emtansine (T-DM1) after surgery, compared with staying on trastuzumab. In triple-negative breast cancer with residual disease, the CREATE-X trial showed a benefit from adjuvant capecitabine.
Pathologists also often report a residual cancer burden score. It grades how much disease is left, from RCB-0 (equivalent to pCR) through RCB-III. That gives a fuller picture than a yes-or-no answer. It can shape both prognosis and further treatment.
Beyond breast cancer
Complete pathologic response is also assessed after neoadjuvant treatment in esophageal, rectal, bladder and lung cancers, among others. It is a good sign wherever it is measured. In rectal cancer it has become central to watch-and-wait strategies for selected people. How strongly it predicts long-term outcome, and what follows from it, varies by cancer type.
Reading your own report
Two things are worth asking about:
- Which definition of pCR was used?
- What does my result change about the treatment ahead?
Those two questions turn a piece of notation into information you can use.
Sources
Common questions
Does pCR mean I am cured?
It means no invasive cancer was found in the tissue that was removed. That is the strongest single result this kind of testing can give and it meaningfully improves the odds. It cannot exclude microscopic cells elsewhere in the body, which is why radiation, endocrine therapy or ongoing HER2-directed treatment are usually still recommended. Most people who achieve pCR do very well; a minority still recur.
My report says ypT0/is ypN0. What does the 'is' part mean?
It means no invasive cancer remained, but some ductal carcinoma in situ was still present. In situ disease has not broken through into surrounding tissue and does not spread. Under the more commonly used FDA definition this still counts as a pathologic complete response, because outcome data track most closely with the elimination of invasive disease.
I did not get a pCR. Does that mean the treatment did not work?
Almost never. Most people have substantial shrinkage without complete disappearance, and that response is real. What residual disease does is give your team direct information about how your cancer behaved, which is used to decide what happens after surgery. In HER2-positive disease, switching to T-DM1 after residual disease improved outcomes in the KATHERINE trial; in triple-negative disease, adjuvant capecitabine did so in CREATE-X.
Why is pCR less meaningful in hormone receptor-positive cancer?
Hormone receptor-positive, HER2-negative cancers usually grow slowly and respond less dramatically to chemotherapy, so pCR is less common. It is also less informative there, because much of the long-term benefit in that group comes from years of endocrine therapy rather than from what chemotherapy achieved before surgery. Tools such as the residual cancer burden score and genomic tests often carry more weight.
Is pCR used outside breast cancer?
Yes. Complete pathologic response after neoadjuvant treatment is assessed in esophageal, rectal, bladder and lung cancers among others, and is generally a favourable finding. The strength of its association with long-term outcome, and what is done about it, differ by cancer type.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Talk with a trained specialist or navigator
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Fever of 100.4°F (38°C) or higher during chemo, severe pain, or trouble breathing: call your cancer care team right away, day or night. Call 911 for an emergency.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer ExplainedSources last checked: 2026-07-30 what this meansLast updated: 2026-08-10Next planned review: 2027-07-30
Review details and limits
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Words to know
Tap any term to see what it means.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.